Scinai Immunotherapeutics Ltd. cotiza a 1.25 USD y tiene una capitalización bursátil de $2M. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Scinai Immunotherapeutics Ltd., together with its subsidiaries, operates as a biopharmaceutical company in Israel and internationally. It engages in the research and development of IL-17 NanoAb, a VHH-based antibody platform for the treatment of immune-mediated and inflammatory diseases, including psoriasis; and PC111,…
| Periodo | 2024-05 | 2023-10 | 2023-08 | 2023-05 |
|---|---|---|---|---|
| Real | $-24.00 | $8.00 | $-12.00 | $-12.00 |
| Estimado | $-6.20 | $-9.40 | $-9.10 | $-7.30 |
| Sorpresa | -287.1% | +185.1% | -31.9% | -64.4% |
| Métrica | SCNI | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | -202.3% | 57.0% | -259.3% |
| Operating Margin | -575.3% | -38.6% | -536.7% |
| Net Margin | -633.6% | -33.6% | -600.1% |
| FCF Margin | -461.9% | -13.9% | -448.0% |
| ROE | -102.5% | -40.4% | -62.1% |
| ROA | -71.5% | -32.0% | -39.4% |
| Current Ratio | 1.30 | 2.84 | -1.54 |
| Debt / Equity | — | 0.28 | — |